Polaris-KY will halt trading tomorrow and announce phase three data of a new drug for mesothelial lung cancer | Anue Juheng – Taiwan Stock News

Polaris – KY (6550-TW) announced today (20) that the stock exchange will suspend trading on the next day (21) due to major information to be announced. The market is speculating that the results of Phase III clinical trial data of the new drug ADI-PEG 20 for mesothelial lung cancer will be published.

The new drug ADI-PEG 20 developed by Polaris is different from the chemotherapy, targeted and immunotherapy used by the general public. Since the new drug has had a rapid review by the US FDA and an extended access policy ( EAP), its mechanism can be applied if the unraveling results are positive.

According to Polaris’ plan, after the new drug for mesothelial lung cancer completes data collection, it will submit a drug certificate to the US FDA as soon as the first quarter of next year, and there is a chance to get a drug certificate at the end 2023 at the earliest.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.